To hear about similar clinical trials, please enter your email below
Trial Title:
Acute Kidney Injury Among Pediatric Cancer Patients At South Egypt Cancer Institute
NCT ID:
NCT06081608
Condition:
To Determine the Cumulative Incidence of AKI Using KDIGO Criteria in Pediatric Patients With Malignancy in South Egypt Cancer Institute (SECI)
Conditions: Official terms:
Acute Kidney Injury
Study type:
Observational [Patient Registry]
Overall status:
Not yet recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
kidney function test
Description:
blood sample for kidney function test
Summary:
Cancer is the second most frequent cause of premature death in children. The incidence of
pediatric cancer varies by region and country, but it is generally considered rare with
an estimated 300,000 new cases diagnosed worldwide. Acute kidney injury in pediatric
cancer patients refers to the sudden and often temporary loss of renal function, which
can lead to a variety of complications if not treated correctly.
Detailed description:
- Primary: To determine the cumulative incidence of AKI using KDIGO criteria in
pediatric patients with malignancy in South Egypt Cancer Institute (SECI)
- Secondary:
1. Incidence of Hospital-acquired and community-acquired AKI
2. Asses the risk factors of the incidence of AKI
3. To determine in-hospital outcome (time to in-hospital death, length of hospital
stay, and time to kidney recovery) of AKI.
This is a prospective study that will be carried out in the Paediatric Oncology and
Haematological Malignancies Department including patients diagnosed with malignant
tumours and hospitalized from 1st April 2023 for one year duration.
Criteria for eligibility:
Study pop:
•Children of both sexes (aged from 1 month to 18 years at diagnosis)
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- • Children of both sexes (aged from 1 month to 18 years at diagnosis)
- Patients with either hematological malignancies or solid tumors admitted to the
Paediatric Oncology and Haematological Malignancies Department
Exclusion Criteria:
- Children who had an unconfirmed cancer diagnosis.
- Children more than 18 years at diagnosis.
- Children with preexisting chronic kidney disease (CKD) that defined as the presence
of structural or functional kidney damage that persist over minimum of three month
- The patient underwent hematopoietic stem cell transplantation. Patients with 1 s.Cr
level.
- Patient underwent renal transplant.
Gender:
All
Minimum age:
30 Days
Maximum age:
18 Years
Start date:
November 1, 2023
Completion date:
September 1, 2024
Lead sponsor:
Agency:
Assiut University
Agency class:
Other
Source:
Assiut University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06081608
